Comprehensive April 2024 Mass Tort Advertising Campaign Investment Guide

050Comprehensive Investment Analysis After Intake Cost Integration

Roundup

• Target Media & Intake CPA: $2,925. Roundup’s notorious link to non-Hodgkin’s Lymphoma spotlights it in legal circles. A high lead to contract ratio suggests that pinpoint targeting and robust conversion mechanisms can yield substantial advertising returns.
• Criteria:
  • Exposure to Roundup and diagnosis with non-Hodgkin’s Lymphoma, specifically B-Cell Non-Hodgkin’s Lymphoma or Waldenstrom Macroglobulinemia, following at least two years post-initial exposure.

Talcum

• Target Media & Intake CPA: $1,050. The personal nature of Talcum powder cases, primarily associated with ovarian cancer, necessitates a delicately crafted advertising strategy. The competitive adjusted media CPA unveils opportunities for significant ROI through empathetic engagement and precision targeting.
• Criteria:
  • Use of Johnson & Johnson’s Talcum Baby Powder or Shower to Shower, culminating in a diagnosis of ovarian, endometrial/uterine, fallopian tube cancer, or leiomyosarcoma.

Paraquat

• Target Media & Intake CPA: $2,800. The unique nexus between Paraquat and Parkinson’s disease carves out a specialized market for legal advertising. The exclusivity of exposure prerequisites demands a targeted campaign blueprint to efficaciously identify and convert leads.
• Criteria:
  • Diagnosis of Parkinson’s Disease post-exposure to Paraquat, with exposure dating back to post-1961, targeting certified applicators, farmers, or those residing near treated farms.

Chemical Hair Straighteners / Relaxers

• Target Media & Intake CPA: $775. The burgeoning awareness of the health hazards posed by chemical hair products is spurring legal action interest. The lower CPA heralds the potential to corner an expanding market with focused communication.
• Criteria:
  • Diagnosis with uterine, endometrial, breast, or ovarian cancer following prolonged use (minimum of 2 years and at least 4 applications per year) of chemical hair straighteners/relaxers, with no current smoking history.

Bard PowerPort

• Target Media & Intake CPA: $900. Focused on device malfunctions, Bard PowerPort cases necessitate refined marketing strategies to reach impacted individuals. The suggested CPA implies that moderate investment could leverage considerable case acquisition in this emerging sector.
• Criteria:
  • Complications post-implantation of Bard PowerPort catheters post-2007, including device fracture/migration leading to severe health outcomes like heart attacks, strokes, or sepsis.

Ozempic

• Target Media & Intake CPA: $850-1,300. The litigious wave instigated by Ozempic and analogous drugs’ side effects underscores the need for finely honed advertising strategies. The CPA range advises a balanced approach to outreach, ensuring broad yet specific target engagement.
• Criteria:
  • Administration of Ozempic, Wegovy, Rybelsus, Mounjaro, or Zepbound for a minimum duration of 30 days, followed by diagnoses such as chronic vomiting, bowel or intestinal obstruction necessitating surgery, gastroparesis requiring surgical intervention, DVT, or ileus, among others, without a pre-existing history of these conditions and age 72 or below at diagnosis time.

AFFF

• Target Media & Intake CPA: $4,470. The environmental and health repercussions of AFFF firefighting foam have galvanized public and legal scrutiny. The elevated CPA indicates the dual challenge and opportunity of engaging with affected demographics through meaningful outreach.
• Criteria:
  • Direct exposure to AFFF firefighting foam and subsequent health issues directly attributable to this exposure, including but not limited to cancers and other severe conditions.

Truvada

• Target Media & Intake CPA: $750. The contention surrounding TDF drugs, particularly Truvada, over undisclosed side effects spotlight the need for judicious advertising. The CPA suggests an efficient pathway to connect with affected individuals through informed messaging strategies.
• Criteria:
  • Consumption of Truvada or other TDF drugs (Viread, Atripla, Complera, Stribild) between 2001 and 2016, leading to severe health conditions such as reduced kidney function, chronic kidney disease, acute kidney injury or failure, Fanconi syndrome, ESRD, osteopenia, osteoporosis, osteomalacia, atraumatic bone fractures, or significant bone loss.